Delhi-based Max Healthcare expects to see a sizeable benefit from the recent revision of Central Government Health Scheme (CGHS) rates.

According to Abhay Soi, Chairman and MD of Max Healthcare , the change will boost financial performance. “This should give us a fillip of over ₹200 crore towards the top line by FY27, and almost 85–90% of it should flow to EBITDA as well,” he said.

The CGHS price overhaul — the first major update in nearly 15 years — came into effect on October 13. The revised schedule includes updated rates for nearly 2,000 medical procedures across empanelled hospitals.

In July-September quarter (Q2FY26), Max Healthcare reported a revenue of ₹2,580 crore, margin of 16.9% and profit of ₹554 crore.

International patients now contribute around 9% of Max Healthcare

See Full Page